Exebacase(CF-301)对感染性心内膜炎患者分离的金黄色葡萄球菌和凝固酶阴性葡萄球菌的体外活性
该研究评估了exebacase对2010-2020年某大学医院感染性心内膜炎患者分离的211株葡萄球菌的体外活性。Exebacase抑制所有金黄色葡萄球菌的MIC≤1 mg/L,对MSSA和MRSA的几何平均MIC分别为0.56和0.49 mg/L;对表皮葡萄球菌的几何平均MIC为3.03(MSSE)和3.40 mg/L(MRSE)。其活性与β-内酰胺类、万古霉素和达托霉素相当,且不受甲氧西林耐药影响。
要点
- Exebacase对金黄色葡萄球菌活性高,MIC≤1 mg/L,且不受甲氧西林耐药影响。
- 对表皮葡萄球菌活性较低,几何平均MIC约3-3.4 mg/L,MIC90达8-16 mg/L。
- Exebacase体外活性与β-内酰胺类、万古霉素和达托霉素相当。
核心结论
- Exebacase的体外活性独立于甲氧西林耐药,对金黄色葡萄球菌的活性始终高于表皮葡萄球菌。
研究设计与样本
- 研究分析了2010-2020年某大学医院感染性心内膜炎患者分离的211株连续菌株,包括金黄色葡萄球菌103株(82 MSSA,21 MRSA)、表皮葡萄球菌76株(20 MSSE,56 MRSE)和其他CoNS 32株。
- 采用肉汤微量稀释法测定exebacase及对照药物(氯唑西林、头孢洛林、万古霉素、达托霉素、庆大霉素、利福平)的MIC。
主要发现
- Exebacase抑制所有金黄色葡萄球菌在≤1 mg/L,MSSA和MRSA的几何平均MIC分别为0.56和0.49 mg/L,MIC50/90为0.5/1 mg/L。
- 表皮葡萄球菌的几何平均MIC为3.03 mg/L(MSSE)和3.40 mg/L(MRSE),MIC50/90分别为4/16和4/8 mg/L。
- 其他CoNS的几何平均MIC范围为0.49 mg/L(头状葡萄球菌)至2.59 mg/L(路邓葡萄球菌),溶血葡萄球菌1.15、人葡萄球菌1.0、施氏葡萄球菌0.79 mg/L。
- Exebacase活性与β-内酰胺类、万古霉素和达托霉素相当,且不受耐药性影响。
临床怎么用
- Exebacase对金黄色葡萄球菌(包括MRSA)感染性心内膜炎可能具有潜在治疗价值,但对表皮葡萄球菌活性较低。
局限性
- 研究为体外药敏试验,未评估临床疗效或体内活性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infective endocarditis (IE) is a severe infection mainly caused by Staphylococcus aureus, Enterococcus faecalis and viridans streptococci. Coagulase-negative staphylococci (CoNS), especially methicillin-resistant Staphylococcus epidermidis (MRSE), are major pathogens in prosthetic valves and devices. Exebacase is a first-in-class, antistaphylococcal lysin with rapid bactericidal and antibiofilm activity. OBJECTIVE: To assess the in vitro activity of exebacase and standard IE antibiotics against S. aureus and CoNS isolates from IE patients in a university hospital (2010-2020). METHODS: A total of 211 consecutive strains were analysed: S. aureus [n = 103 (82 MSSA, 21 MRSA)], S. epidermidis [n = 76 (20 MSSE, 56 MRSE)] and other CoNS species (n = 32, Staphylococcus haemolyticus, Staphylococcus lugdunensis, Staphylococcus hominis, Staphylococcus capitis, Staphylococcus schleiferi, Staphylococcus caprae, Staphylococcus pasteuri). Broth microdilution MICs were determined for exebacase and comparators (cloxacillin, ceftaroline, vancomycin, daptomycin, gentamicin, rifampicin). RESULTS: Exebacase inhibited all S. aureus at ≤1 mg/L. Geometric mean (GM) MICs were 0.56 mg/L for MSSA and 0.49 mg/L for MRSA, with MIC50/90 of 0.5/1 mg/L. For S. epidermidis, GM MICs were 3.03 mg/L (MSSE) and 3.40 mg/L (MRSE), with MIC50/90 of 4/16 and 4/8 mg/L, respectively. Other CoNS showed GM MICs ranging from 0.49 mg/L (S. capitis) to 2.59 mg/L (S. lugdunensis), with intermediate values for S. haemolyticus (1.15), S. hominis (1.0) and S. schleiferi (0.79). Exebacase activity was comparable to β-lactams, vancomycin and daptomycin and remained unaffected by resistance. CONCLUSIONS: Exebacase activity was independent of methicillin resistance and consistently higher against S. aureus than S. epidermidis. Further research is warranted to explore lysins in combination against staphylococcal infections.
引用
- Cañas MA, Cuervo G, García-González J, et al. In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis. J Antimicrob Chemother. 2026. PMID: 41342135. doi:10.1093/jac/dkaf435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。